Biotechnology - Therapeutics/Diagnostics Private/independent Companies All units in USD M Year

Transcription

1

2

3

4

5

6 Biotechnology - Therapeutics/Diagnostics Private/ Companies All units in USD M Year Grand Month Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Total Total US Europe Rest of World

7 Company Name Sector Amount musd Type of Round Financing Stage Ownership Country Cara Therapeutics Therapeutics/Diagnostics 55.0 Other IPO Public Trevena, Inc Therapeutics/Diagnostics 64.8 Other IPO Public CytRx Corporation Therapeutics/Diagnostics 74.8 Other Post-IPO Public BioCryst Therapeutics/Diagnostics 2.5 Other Research Public Pharmaceuticals, grants Celladon Corporation Therapeutics/Diagnostics 44.0 Other IPO Public TESARO, Therapeutics/Diagnostics Other Post-IPO Public Geron Corporation Therapeutics/Diagnostics 90.0 Other Post-IPO Public Dicerna Pharmaceuticals, Therapeutics/Diagnostics 90.0 Other IPO Public Igenica, Therapeutics/Diagnostics 14.0 Series C / 3. Round Second SQI Diagnostics R&D Services 1.2 Other Post-IPO Public Canada MYOS Corporation Biotechnology - other 4.7 Other Post-IPO Public Augurix SA Medical Technology 3.3 Other Switzerland Later Ceres, Biotechnology - other 20.0 Other Post-IPO Public Epizyme, Therapeutics/Diagnostics Other Post-IPO Public

8 TONIX Pharmaceuticals Holding Corp. Therapeutics/Diagnostics 43.5 Other Post-IPO Public Akers Biosciences, Medical Technology 15.0 Other Post-IPO Public Genmab A/S Therapeutics/Diagnostics Other Post-IPO Public Denmark Microvi Biotechnologies Biotechnology - other 1.5 Other Research grants Keryx Biopharmaceuticals, Therapeutics/Diagnostics Other Post-IPO Public NanoString Technologies, R&D Services 55.0 Other Post-IPO Public Acceleron Pharma, Therapeutics/Diagnostics Other Post-IPO Public Nektar Therapeutics Therapeutics/Diagnostics Other Post-IPO Public Cohera Medical, Medical Technology 9.3 Series D / 4. Round First Oncovet Clinical R&D Services 1.4 Series A / Public France Research 1. Round Synthelis R&D Services 0.8 Other France nlife Therapeutics Therapeutics/Diagnostics 3.1 Other First Spain GlycoMimetics, Therapeutics/Diagnostics 57.4 Other IPO Public Amorfix Life Sciences Ltd. Therapeutics/Diagnostics 0.3 Other Other Public Canada Receptos, Therapeutics/Diagnostics Other Post-IPO Public ProNAi Therapeutics, Therapeutics/Diagnostics 12.0 Series C / 3. Round Second

9 Ivantis, Medical Technology 14.0 Series B / 2. Round Second Michelson Diagnostics Medical Technology 3.3 Other Other Ltd. United Kingdom Galectin Therapeutics Therapeutics/Diagnostics 23.9 Other Post-IPO Public Atara Biotherapeutics, Therapeutics/Diagnostics 52.0 Series B / 2. Round Second Retrophin, Therapeutics/Diagnostics 40.0 Other Post-IPO Public Athersys, Therapeutics/Diagnostics 20.5 Other Post-IPO Public Knome, R&D Services 13.0 Other Other Avelas Biosciences, Medical Technology 6.9 Series B / 2. Round First GW Pharmaceuticals Therapeutics/Diagnostics 87.9 Other Post-IPO Public United Kingdom AC Immune SA Therapeutics/Diagnostics 22.1 Series D / Switzerland 4. Round Bellicum Therapeutics/Diagnostics 14.7 Series B / Pharmaceuticals, 2. Round Second ImmuneXcite, Therapeutics/Diagnostics 3.6 Series B / 2. Round Auspex Pharmaceuticals Therapeutics/Diagnostics 20.0 Series E / Public 5. Round Omicia, R&D Services 6.8 Series A / 1. Round First Blueprint Medicines Therapeutics/Diagnostics 25.0 Series B / 2. Round Halozyme Therapeutics, Therapeutics/Diagnostics 20.0 Other Other Public

10 Alimera Sciences, Therapeutics/Diagnostics 37.5 Other Post-IPO Public DNAnexus, R&D Services 15.0 Series C / 3. Round Second Metabolon, R&D Services 15.0 Series E / 5. Round First Intra-Cellular Therapies, Therapeutics/Diagnostics Other Post-IPO Public

11